

Colin Baigent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9506352/publications.pdf>

Version: 2024-02-01

133
papers

40,512
citations

13827

67
h-index

12558

132
g-index

137
all docs

137
docs citations

137
times ranked

38132
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
2	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	1.0	4,210
3	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet, The</i> , 2009, 373, 1849-1860.	6.3	3,100
4	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
5	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	1.0	2,426
6	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet, The</i> , 2011, 377, 2181-2192.	6.3	2,087
7	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. <i>Lancet, The</i> , 2014, 384, 1929-1935.	6.3	1,971
8	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet, The</i> , 2016, 388, 2532-2561.	6.3	1,399
9	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. <i>Lancet, The</i> , 2015, 385, 1397-1405.	6.3	1,112
10	Low-Dose Aspirin for the Prevention of Atherothrombosis. <i>New England Journal of Medicine</i> , 2005, 353, 2373-2383.	13.9	1,053
11	Revascularization versus Medical Therapy for Renal-Artery Stenosis. <i>New England Journal of Medicine</i> , 2009, 361, 1953-1962.	13.9	1,035
12	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1529-1539.	13.9	823
13	Aspirin in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1494-1503.	13.9	735
14	2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 655-720.	1.0	647
15	COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. <i>Lancet, The</i> , 2020, 396, 381-389.	6.3	521
16	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
17	Effects of ω -3 Fatty Acid Supplements in Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018, 379, 1540-1550.	13.9	510
18	Premature cardiovascular disease in chronic renal failure. <i>Lancet, The</i> , 2000, 356, 147-152.	6.3	502

#	ARTICLE	IF	CITATIONS
19	Antiplatelet Drugs. <i>Chest</i> , 2008, 133, 199S-233S.	0.4	478
20	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021, 397, 1625-1636.	6.3	414
21	Cholesterol and the Risk of Renal Dysfunction in Apparently Healthy Men. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2084-2091.	3.0	352
22	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
23	Expert Consensus Document on the Use of Antiplatelet Agents The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 166-181.	1.0	334
24	Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1997, 336, 847-860.	13.9	308
25	Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. <i>American Journal of Kidney Diseases</i> , 2004, 43, 244-253.	2.1	272
26	Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy. <i>PLoS ONE</i> , 2012, 7, e29849.	1.1	270
27	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	1.2	257
28	Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 199-208.	3.7	244
29	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology, the</i> , 2016, 4, 829-839.	5.5	234
30	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
31	Analyses of Cancer Data from Three Ezetimibe Trials. <i>New England Journal of Medicine</i> , 2008, 359, 1357-1366.	13.9	230
32	Diabetes and Cause-Specific Mortality in Mexico City. <i>New England Journal of Medicine</i> , 2016, 375, 1961-1971.	13.9	207
33	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
34	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 749-761.	1.4	196
35	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. <i>Stroke</i> , 2016, 47, 2373-2379.	1.0	193
36	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. <i>Lancet Neurology, The</i> , 2016, 15, 925-933.	4.9	187

#	ARTICLE	IF	CITATIONS
37	First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2005, 45, 473-484.	2.1	184
38	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	1.8	165
39	Statins and diabetes – Authors' reply. <i>Lancet, The</i> , 2008, 371, 1752.	6.3	160
40	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1801-1807.	1.2	156
41	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 231-241.	3.7	156
42	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
43	Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1082-1094.	2.1	144
44	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1825-1833.	3.0	142
45	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1760-1776.	1.2	140
46	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	3.0	140
47	Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. <i>Lancet, The</i> , 2019, 393, 2613-2623.	6.3	134
48	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021, 398, 1053-1064.	6.3	133
49	Ensuring trial validity by data quality assurance and diversification of monitoring methods. <i>Clinical Trials</i> , 2008, 5, 49-55.	0.7	129
50	Statins for people at low risk of cardiovascular disease – Authors' reply. <i>Lancet, The</i> , 2012, 380, 1817-1818.	6.3	127
51	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007, 28, 880-913.	1.0	119
52	Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1009-1020.	6.3	119
53	Blood pressure lowering and cardiovascular risk – Authors' reply. <i>Lancet, The</i> , 2014, 384, 1746-1747.	6.3	118
54	Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. <i>Arthritis and Rheumatism</i> , 2003, 48, 12-20.	6.7	110

#	ARTICLE	IF	CITATIONS
55	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	1.0	106
56	The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 385-395.	2.1	104
57	Randomized Clinical Trials "Removing Unnecessary Obstacles. <i>New England Journal of Medicine</i> , 2013, 369, 1061-1065.	13.9	103
58	Nonsteroidal Anti-Inflammatory Drugs and the Heart. <i>Circulation</i> , 2014, 129, 907-916.	1.6	99
59	Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. <i>American Journal of Kidney Diseases</i> , 2001, 38, 537-546.	2.1	97
60	Role of aspirin in primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 675-686.	6.1	97
61	Nepriylsin inhibition in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 738-743.	0.4	80
62	The role of lipoprotein (a) in chronic kidney disease. <i>Journal of Lipid Research</i> , 2018, 59, 577-585.	2.0	77
63	Alteplase for Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 746-756.	1.0	74
64	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 591-598.	2.1	74
65	The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. <i>Kidney International</i> , 2021, 99, 791-793.	2.6	74
66	Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e25920.	1.1	70
67	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. <i>Lancet Neurology</i> , The, 2019, 18, 643-652.	4.9	68
68	Low-Dose Aspirin, Coxibs, and other NSAIDs: A Clinical Mosaic Emerges. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2009, 9, 31-39.	3.4	58
69	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 68, 371-380.	2.1	57
70	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48.	2.1	55
71	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 4-13.	1.8	52
72	Sensible guidelines for the conduct of large randomized trials. <i>Clinical Trials</i> , 2008, 5, 38-39.	0.7	51

#	ARTICLE	IF	CITATIONS
73	Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 455-463.	5.5	50
74	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 35-47.	0.7	49
75	Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. <i>American Heart Journal</i> , 2015, 169, 605-612.	1.2	44
76	Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. <i>Lancet Neurology</i> , 2021, 20, 842-853.	4.9	44
77	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 31-39.	2.1	42
78	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 546-552.	2.2	41
79	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 47-60.	2.2	41
80	Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw095.	0.4	40
81	Chronic kidney disease, heart failure and neprilysin inhibition. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 558-564.	0.4	39
82	Conventional and Genetic Evidence on the Association between Adiposity and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 127-137.	3.0	39
83	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	2.9	36
84	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. <i>International Journal of Stroke</i> , 2018, 13, 175-189.	2.9	36
85	Should We Increase GFR with Bardoxolone in Alport Syndrome?. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 357-359.	3.0	33
86	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. <i>EClinicalMedicine</i> , 2021, 41, 101163.	3.2	33
87	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
88	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 314-322.	1.3	30
89	Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. <i>European Heart Journal</i> , 2020, 41, 3336-3342.	1.0	27
90	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27

#	ARTICLE	IF	CITATIONS
91	Impact of CKD on Household Income. <i>Kidney International Reports</i> , 2018, 3, 610-618.	0.4	25
92	Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage. <i>JAMA Neurology</i> , 2021, 78, 1179.	4.5	25
93	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 685-711.	1.8	24
94	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials. <i>Seminars in Dialysis</i> , 2007, 20, 498-503.	0.7	23
95	Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure?. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1118-1119.	0.4	22
96	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1794-1801.	2.2	22
97	Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. <i>Kidney International</i> , 2018, 93, 1165-1174.	2.6	21
98	Aspirin in primary prevention – good news and bad news. <i>Nature Reviews Cardiology</i> , 2012, 9, 262-263.	6.1	19
99	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19
100	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	2.1	19
101	Biliary Tract and Liver Complications in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2738-2748.	3.0	19
102	Which cardiovascular risk factors matter in chronic kidney disease?. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 9-11.	0.4	18
103	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 1424-1434.	2.6	18
104	B Vitamins for the Prevention of Vascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1212.	3.8	16
105	Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 601-605.	1.0	15
106	Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 4-5.	3.3	15
107	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
108	Relationship between anaemia, coagulation parameters during pregnancy and postpartum haemorrhage at childbirth: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e050815.	0.8	12

#	ARTICLE	IF	CITATIONS
109	Statins: are any questions unanswered?. <i>Current Opinion in Lipidology</i> , 2006, 17, 418-425.	1.2	10
110	Misrepresentation of statin safety evidence. <i>Lancet, The</i> , 2014, 384, 1263-1264.	6.3	10
111	Efficacy and safety of cholesterol-lowering treatment – Authors' reply. <i>Lancet, The</i> , 2006, 367, 470-471.	6.3	9
112	Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank. <i>International Journal of Obesity</i> , 2020, 44, 2256-2266.	1.6	9
113	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 2030-2037.	0.8	8
114	Coxibs and traditional NSAIDs for pain relief – Authors' reply. <i>Lancet, The</i> , 2014, 383, 122.	6.3	7
115	Clinical trial recommendations for potential Alport syndrome therapies. <i>Kidney International</i> , 2020, 97, 1109-1116.	2.6	7
116	Efficacy and safety of more intensive lowering of LDL cholesterol – Authors' reply. <i>Lancet, The</i> , 2011, 377, 715-716.	6.3	6
117	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw396.	0.4	6
118	Cholesterol Metabolism and Statin Effectiveness in Hemodialysis Patients –. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2299-2301.	1.2	5
119	Thrombolysis in acute stroke – Authors' reply. <i>Lancet, The</i> , 2015, 385, 1396.	6.3	5
120	Aspirin for Disease Prevention: Public Policy or Personal Choice?. <i>Annals of Internal Medicine</i> , 2016, 164, 846.	2.0	4
121	Aspirin for asymptomatic atherosclerosis?. <i>Nature Reviews Cardiology</i> , 2010, 7, 306-307.	6.1	3
122	PCSK9 inhibition: a new player in cholesterol-lowering therapies?. <i>Nature Reviews Nephrology</i> , 2017, 13, 450-451.	4.1	3
123	Variability in aspirin efficacy: all in the genes?. <i>European Heart Journal</i> , 2019, 40, 3393-3396.	1.0	3
124	What is the association of COVID-19 with heart attacks and strokes?. <i>Lancet, The</i> , 2021, 398, 561-563.	6.3	3
125	Benefits of lowering cholesterol in chronic kidney disease – Authors' reply. <i>Lancet, The</i> , 2011, 378, 1377-1378.	6.3	1
126	Air pollution and traffic noise: do they cause atherosclerosis?. <i>European Heart Journal</i> , 2014, 35, 826-828.	1.0	1

#	ARTICLE	IF	CITATIONS
127	Safety and efficacy of statins – Authors' reply. Lancet, The, 2017, 389, 1099-1100.	6.3	1
128	Clopidogrel reduced stroke, MI, and vascular death compared with aspirin. ACP Journal Club, 1997, 126, 59.	0.1	1
129	Benefit of aspirin plus angiotensin-converting enzyme inhibitor. Journal of the American College of Cardiology, 2001, 37, 1474-1475.	1.2	0
130	Review of The struggle for life: A psychological perspective of kidney disease and transplantation. American Journal of Kidney Diseases, 2004, 44, 382.	2.1	0
131	Aspirin in the primary prevention of vascular disease – ATT secretariat's reply. Lancet, The, 2009, 374, 879.	6.3	0
132	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. Clinica Chimica Acta, 2015, 439, 112-114.	0.5	0
133	Questioning statin therapy for older patients – Authors' reply. Lancet, The, 2020, 395, 1832-1833.	6.3	0